The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. (Other OTC: INSD) who purchased shares between December 8, 2020 and November 24, 2021. The action, which was filed in the United States District Court for the Eastern District of Virginia, alleges that the Company violated federal securities laws.
In particular, the Instadose lawsuit alleges that (i) Instadose had performed inadequate due diligence into the business combination with Instadose Canada and/or ignored significant red flags associated with Instadose Canada; (ii) Instadose’s internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company; (iii) the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until February 28, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >